GlassScriptPhysician profile
Randy A Mudge
NPI 1346200573
$2,396.12
in general payments reported to CMS, 2019-2025
46 companies · $547 in 2025
The $547 reported for 2025 was more than what 76% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $14.03 · 2022: $391 · 2023: $534 · 2024: $710 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $248.28 | 2019-2025 | |
| Astellas Pharma US INC | $211.13 | 2022-2024 | Xtandi |
| Sirtex Medical INC | $192.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.19 | 2019-2025 | |
| Intuitive Surgical, INC. | $98.51 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $93.32 | 2023-2025 | Imfinzi, Onglyza, Calquence |
| Varian Medical Systems, INC. | $91.01 | 2019 | |
| Tempus Ai, INC | $85.32 | 2024-2025 | Xt Cdx, Tempus Pixel |
| Takeda Pharmaceuticals U.S.A., INC. | $84.41 | 2023-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Merck Sharp & Dohme LLC | $83.57 | 2023-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $81.76 | 2019-2025 | Darzalex, Tecvayli |
| Genzyme Corporation | $71.43 | 2023-2025 | |
| Daiichi Sankyo INC. | $70.45 | 2024-2025 | Injectafer, Enhertu |
| Genentech USA, INC. | $54.40 | 2023-2025 | Venclexta |
| Pharmacosmos Therapeutics INC. | $54.29 | 2023-2025 | Monoferric, Cosela |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $52.25 | 2024-2025 | Brukinsa |
| Seagen INC. | $46.07 | 2023 | Tukysa, Padcev |
| Gilead Sciences, INC. | $45.11 | 2023-2024 | Trodelvy |
| Lilly USA, LLC | $39.42 | 2023-2025 | Verzenio, Jaypirca |
| Incyte Corporation | $37.35 | 2023-2025 | Monjuvi, Jakafi |
| Abbvie INC. | $36.20 | 2024-2025 | |
| Puma Biotechnology, INC. | $32.57 | 2023-2025 | |
| Pfizer INC. | $31.00 | 2024-2025 | |
| Geron Corporation | $30.35 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $28.76 | 2024-2025 | |
| Adc Therapeutics America, INC. | $28.19 | 2025 | |
| Kite Pharma, INC. | $27.07 | 2025 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $26.79 | 2024 | Onivyde, Somatuline Depot |
| Agios Pharmaceuticals, INC. | $23.25 | 2024 | Pyrukynd |
| Eisai INC. | $21.24 | 2023 | |
| Coherus Oncology, INC. | $20.97 | 2024 | |
| Sobi, INC | $20.67 | 2024 | |
| Blueprint Medicines Corporation | $20.38 | 2023 | Ayvakit |
| Exelixis INC. | $19.88 | 2019 | |
| Progenics Pharmaceuticals, INC. | $19.28 | 2023 | Pylarify |
| Alnylam Pharmaceuticals INC. | $18.39 | 2023 | Givlaari |
| Emd Serono, INC. | $18.32 | 2024 | |
| Taiho Oncology, INC. | $17.39 | 2022 | |
| Emmaus Medical, INC. | $16.93 | 2024 | Endari |
| Glaxosmithkline, LLC. | $16.25 | 2025 | Ojjaara |
| G1 Therapeutics, INC. | $15.18 | 2023 | Cosela |
| Fortovia Therapeutics, INC. | $14.03 | 2020 | |
| Boston Scientific Corporation | $13.48 | 2025 | Spaceoar Vue System - 10ml |
| Clovis Oncology, INC. | $13.42 | 2019 | |
| Rigel Pharmaceuticals, INC. | $11.18 | 2024 | Rezlidhia, Tavalisse |
| Amgen INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Mudge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.